Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis.

Jenni D, Karpova MB, Mühleisen B, Mangana J, Dreier J, Hafner J, Dummer R.

ESMO Open. 2016 Jan 18;1(1):e000003. eCollection 2016.

2.

In vivo profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma.

Urosevic-Maiwald M, Barysch MJ, Cheng PF, Karpova MB, Steinert H, Okoniewski MJ, Dummer R.

Oncoimmunology. 2015 Jan 7;4(2):e988458. eCollection 2015 Feb. Erratum in: Oncoimmunology. 2016 Feb 17;5(1):e1104009.

3.

Versican upregulation in Sézary cells alters growth, motility and resistance to chemotherapy.

Fujii K, Karpova MB, Asagoe K, Georgiev O, Dummer R, Urosevic-Maiwald M.

Leukemia. 2015 Oct;29(10):2024-32. doi: 10.1038/leu.2015.103. Epub 2015 Apr 27.

PMID:
25915825
4.

Coexpression of SOX10/CD271 (p75(NTR)) and β-Galactosidase in Large to Giant Congenital Melanocytic Nevi of Pediatric Patients.

Barysch MJ, Levesque MP, Cheng P, Karpova MB, Mihic-Probst D, Civenni G, Shakhova O, Sommer L, Biedermann T, Schiestl C, Dummer R.

Dermatopathology (Basel). 2014 May 1;1(1):35-46. doi: 10.1159/000362490. eCollection 2014 Jan-Jul.

5.

Complete absence of the αGal xenoantigen and isoglobotrihexosylceramide in α1,3galactosyltransferase knock-out pigs.

Puga Yung GL, Li Y, Borsig L, Millard AL, Karpova MB, Zhou D, Seebach JD.

Xenotransplantation. 2012 May-Jun;19(3):196-206. doi: 10.1111/j.1399-3089.2012.00705.x.

6.

Sorafenib in melanoma.

Mangana J, Levesque MP, Karpova MB, Dummer R.

Expert Opin Investig Drugs. 2012 Apr;21(4):557-68. doi: 10.1517/13543784.2012.665872. Epub 2012 Mar 7. Review.

PMID:
22394203
7.

Cutaneous lymphomas: molecular pathways leading to new drugs.

Dummer R, Goldinger SM, Cozzio A, French LE, Karpova MB.

J Invest Dermatol. 2012 Mar;132(3 Pt 1):517-25. doi: 10.1038/jid.2011.370. Epub 2011 Dec 8. Review.

8.

Changing pathology with changing drugs: skin cancer.

Karpova MB, Barysch MJ, Zipser MC, Schönewolf N, French LE, Dummer R.

Pathobiology. 2011;78(2):61-75. doi: 10.1159/000314576. Epub 2011 Jun 14. Review.

9.

Split-face study of melasma patients treated with non-ablative fractionated photothermolysis (1540 nm).

Barysch MJ, Rümmelein B, Kolm I, Karpova MB, Schönewolf N, Bogdan Allemann I, Dummer R.

J Eur Acad Dermatol Venereol. 2012 Apr;26(4):423-30. doi: 10.1111/j.1468-3083.2011.04086.x. Epub 2011 Apr 27.

PMID:
21521377
10.

High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade.

Kiessling MK, Oberholzer PA, Mondal C, Karpova MB, Zipser MC, Lin WM, Girardi M, Macconaill LE, Kehoe SM, Hatton C, French LE, Garraway LA, Polier G, Süss D, Klemke CD, Krammer PH, Gülow K, Dummer R.

Blood. 2011 Feb 24;117(8):2433-40. doi: 10.1182/blood-2010-09-305128. Epub 2011 Jan 5.

11.

Primary cutaneous lymphoma: two-decade comparison in a population of 263 cases from a Swiss tertiary referral centre.

Jenni D, Karpova MB, Seifert B, Golling P, Cozzio A, Kempf W, French LE, Dummer R.

Br J Dermatol. 2011 May;164(5):1071-7. doi: 10.1111/j.1365-2133.2010.10143.x.

PMID:
21083546
12.

Evaluation of lymphangiogenic markers in Sézary syndrome.

Karpova MB, Fujii K, Jenni D, Dummer R, Urosevic-Maiwald M.

Leuk Lymphoma. 2011 Mar;52(3):491-501. doi: 10.3109/10428194.2010.517877. Epub 2010 Sep 17.

PMID:
20846094
13.

Primary cutaneous CD30+ anaplastic large-cell lymphomas show a heterogeneous genomic profile: an oligonucleotide arrayCGH approach.

Sánchez-Schmidt JM, Salgado R, Servitje O, Gallardo F, Ortiz-Romero PL, Karpova MB, Zipser MC, García-Muret MP, Estrach T, Rodríguez-Pinilla SM, Climent F, Suela J, Ferreira BI, Cigudosa JC, Salido M, Barranco C, Serrano S, Dummer R, Solé F, Pujol RM, Espinet B.

J Invest Dermatol. 2011 Jan;131(1):269-71. doi: 10.1038/jid.2010.271. Epub 2010 Sep 16. No abstract available.

14.

MEK1 mutations confer resistance to MEK and B-RAF inhibition.

Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, MacConaill LE, Zhang J, Gray NS, Sellers WR, Dummer R, Garraway LA.

Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20411-6. doi: 10.1073/pnas.0905833106. Epub 2009 Nov 13.

15.

Oligonucleotide array-CGH identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides.

Salgado R, Servitje O, Gallardo F, Vermeer MH, Ortiz-Romero PL, Karpova MB, Zipser MC, Muniesa C, García-Muret MP, Estrach T, Salido M, Sánchez-Schmidt J, Herrera M, Romagosa V, Suela J, Ferreira BI, Cigudosa JC, Barranco C, Serrano S, Dummer R, Tensen CP, Solé F, Pujol RM, Espinet B.

J Invest Dermatol. 2010 Apr;130(4):1126-35. doi: 10.1038/jid.2009.306. Epub 2009 Sep 17.

17.

Combined CYP1A1/GSTM1 at-risk genotypes are overrepresented in squamous cell lung carcinoma patients but underrepresented in elderly tumor-free subjects.

Belogubova EV, Ulibina YM, Suvorova IK, Kuligina ESh, Karpova MB, Shutkin VA, Koloskov AV, Kuchinskiy AP, Togo AV, Hanson KP, Hirvonen A, Imyanitov EN.

J Cancer Res Clin Oncol. 2006 May;132(5):327-31. Epub 2006 Jan 14.

PMID:
16416283
18.

Betulinic acid, a natural cytotoxic agent, fails to trigger apoptosis in human Burkitt's lymphoma-derived B-cell lines.

Karpova MB, Sanmun D, Henter JI, Smirnov AF, Fadeel B.

Int J Cancer. 2006 Jan 1;118(1):246-52.

19.

'Comparison of extremes' approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility.

Belogubova EV, Kuligina ESh, Togo AV, Karpova MB, Ulibina JM, Shutkin VA, Hanson KP, Popowski K, Mosyagin I, Cascorbi I, Hirvonen A, Imyanitov EN.

Cancer Lett. 2005 Apr 28;221(2):177-83.

PMID:
15808403
20.

Raji revisited: cytogenetics of the original Burkitt's lymphoma cell line.

Karpova MB, Schoumans J, Ernberg I, Henter JI, Nordenskjöld M, Fadeel B.

Leukemia. 2005 Jan;19(1):159-61. No abstract available.

PMID:
15457187
21.

Phosphatidylserine externalization in cardiolipin-deficient cells.

Fadeel B, Karpova MB, Enoksson M, Orrenius S.

Blood. 2004 Sep 1;104(5):1582-3; author reply 1583-4. No abstract available.

22.

[Allelic distribution of the CYP1A1 in lung cancer patients, middle-aged tissue donors and in elderly people without cancer].

Belogubova EV, Togo AV, Suvorova IK, Karpova MB, Ulybina IuM, Zaĭtseva OA, Iatsuk OS, Shutkin VA, Riabokon' SA, Ievleva AG, Chekmarëva EV, Lemekhov VG, Koloskov AV, Kuchinskiĭ AP, Khanson KP, Imianitov EN.

Vopr Onkol. 2004;50(2):165-8. Russian.

PMID:
15176217
23.

A novel approach for assessment of cancer predisposing roles of GSTM1 and GSTT1 genes: use of putatively cancer resistant elderly tumor-free smokers as the referents.

Belogubova EV, Togo AV, Karpova MB, Kuligina ESh, Buslova KG, Ulibina JM, Lemehov VG, Romanenko SM, Shutkin VA, Hanson KP, Hirvonen A, Imyanitov EN.

Lung Cancer. 2004 Mar;43(3):259-66.

PMID:
15165083
24.

[Genetic polymorphism of steroid 17 alpha-hydroxylase/17,20-lyase (CYP17) and hyperinsulinemia in endometrial carcinoma].

Berstein LM, Imianitov EN, Gamaiunova VB, Kovalevskiĭ AIu, Kuligina ESh, Belogubova EV, Buslov KG, Karpova MB, Togo AV, Volkov ON, Kovalenko IG, Chernobrovkina AE.

Vopr Onkol. 2002;48(6):673-8. Russian.

PMID:
12530262
25.

CYP17 genetic polymorphism in endometrial cancer: are only steroids involved?

Berstein LM, Imyanitov EN, Gamajunova VB, Kovalevskij AJ, Kuligina ESh, Belogubova EV, Buslov KG, Karpova MB, Togo AV, Volkov ON, Kovalenko IG.

Cancer Lett. 2002 Jun 6;180(1):47-53.

PMID:
11911969
26.

L-myc polymorphism in cancer patients, healthy blood donors and elderly, tumor-free individuals in Russia.

Togo AV, Suspitsin EN, Grigoriev MY, Ilyushik ES, Karpova MB, Hanson KP, Imyanitov EN.

Int J Cancer. 2000 Mar 15;85(6):747-50.

Supplemental Content

Loading ...
Support Center